Rapport Therapeutics, Inc. (RAPP) · Aug 5, 2026 · Company update

Loss missed consensus as pivotal epilepsy trial launch stayed on schedule

Loss missed consensus as pivotal epilepsy trial launch stayed on schedule

The quarter missed on the one reported financial benchmark. GAAP loss per share was $1.19, versus published consensus of roughly $0.97; the loss also widened from $0.75 a year earlier. The miss reflects a sharp ramp in clinical-development spending rather than a revenue shortfall—Rapport remains a clinical-stage company without product revenue.

MetricQ2 2026ComparisonWhat changed
Net loss per share$(1.19)Consensus: about $(0.97); Q2 2025: $(0.75)Worse than both expectations and prior year (Statement of Operations)
Net loss$(56.6M)Q2 2025: $(26.7M)More than doubled as the development program expanded (Statement of Operations)
R&D expense$51.4MQ2 2025: $22.7MSpending ramped with pivotal-trial and pipeline activity (Statement of Operations)
Cash, equivalents and short-term investments$436.1M$476.8M at March 31, 2026Down $40.7M sequentially, while runway guidance was retained (Financial Results; Cash Flow statement)
Cash runwayInto 2H 2029Unchanged from the prior updateNo new financing need was introduced (Cash Runway)

The headline clinical milestone was delivered, but it was already expected. FOCUS 1 and FOCUS 2 are now enrolling in Phase 3 for focal onset seizures, matching management's prior target to initiate the program in the second quarter. China IND clearance and enrollment in the long-term safety study reinforce execution, but the filing brings no new controlled efficacy data or accelerated pivotal timeline. That makes this progress supportive of the existing thesis, not a fresh clinical upside surprise (Corporate Highlights — RAP-219 in Epilepsy).

Previously disclosed Phase 2 follow-up data should not be treated as new de-risking. The release repeats April-presented open-label results, including median clinical-seizure reductions of 90% in weeks 9–12 and 59% in weeks 13–16. The updated 22-day half-life estimate may support less-frequent dosing potential, but it is pharmacokinetic modeling rather than a new efficacy readout (Corporate Highlights — Follow-up Phase 2a Data; RAP-219 Half-Life).

The next genuine value-setting event is still ahead. Bipolar-mania Phase 2 topline data remain due in October 2026. Increasing enrollment and revising the statistical plan could allow a successful study to serve as confirmatory evidence, but that is only an option contingent on the data; the filing does not reduce that clinical risk today (Additional Pipeline Updates — Bipolar Mania Phase 2 Trial).

Net: the company preserved its long cash runway and executed against the expected Phase 3 start, but the earnings loss was worse than consensus and no new efficacy catalyst arrived.

Original filing on SEC EDGAR

More Rapport Therapeutics, Inc. news

Loss missed consensus as pivotal epilepsy trial launch stayed on schedule | RAPP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.